Merck & Co. has shown why it bet $250 million on Moderna’s mRNA cancer immunotherapy. Weeks after Merck opted into the program, the partners have revealed the personalized candidate reduced the risk of recurrence or death by 44% when given to melanoma patients in combination with Keytruda.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,